[Neurochemical aspects and pharmacological implications in essential tremor (preliminary note)].
D000613:Aminobutyrates / Q000378:metabolism*; D001921:Brain / Q000378:metabolism*; D002230:Carbidopa / Q000627:therapeutic use*; D004576:Electromyography; D006220:Haloperidol / Q000627:therapeutic use*; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010525:Peripheral Nerves / Q000378:metabolism*; D011395:Promazine / Q000627:therapeutic use*; D014202:Tremor / Q000188:drug therapy / Q000503:physiopathology*; D014631:Valerates / Q000627:therapeutic use*; D014635:Valproic Acid / Q000627:therapeutic use*; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
D000613:Aminobutyrates; D006834:Hydrazines; D014631:Valerates; D007980:Levodopa; D005680:gamma-Aminobutyric Acid; D014635:Valproic Acid; D006220:Haloperidol; D002230:Carbidopa; D011395:Promazine
Aspetti neurochimici ed implicazioni farmacologiche nel tremore di atteggiamento.